Matrix metalloproteinase inhibitor

DolCas Biotech Obtains its First Non-GMO Project Verified Label for MMP-50®

Retrieved on: 
Wednesday, September 13, 2023
ASC, DNA, Communication, Medicine, Human, Mineral, Matrix metalloproteinase, Aquaculture Stewardship Council, Bureau of Oceans and International Environmental and Scientific Affairs, Marketing, Horse, NSF, The Non-GMO Project, Matrix metalloproteinase inhibitor, GMO, Lipid, USP, Certification, Economic methodology, Vitamin, Beauty, Tilapia, USDA, Mukai Cold Process Fruit Barrelling Plant, Dog, Micronutrient, Health, Environment, News, NMI, Aquaculture, Dietary supplement

LANDING, N.J., Sept. 13, 2023 /PRNewswire/ -- DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health. MMP-50 is one of seven clinically researched ingredients in the innovative company's portfolio, and while MMP-50 is the first to receive the backing of the prestigious certification, CEO and founder, K. G. Rao affirms the company's plans to pursue the certification across its portfolio.

Key Points: 
  • LANDING, N.J., Sept. 13, 2023 /PRNewswire/ -- DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health.
  • The transparency efforts the Non-GMO Project spearheaded on the food front has translated to the supplement market.
  • DolCas voluntarily submitted MMP-50 for compliance evaluation with the Non-GMO Project standard.
  • Like the Non-GMO Verified Project, the ASC certificate is the most highly merited of third-party credentialing in its category.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
Wednesday, May 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.

Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2019
Health, Pharmaceutical, Matrix metalloproteinases, Matrix metalloproteinase, Metalloproteinase, Branches of biology, Chemistry, Metalloprotease inhibitor, Molecular biology, Matrix metalloproteinase inhibitor

The "Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Matrix Metalloproteinase (MMP) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Matrix Metalloproteinase (MMP) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.